['The role of thyrotropin (TSH) on the cardiovascular system has been poorly investigated. It is unknown whether the changes in the vasculature associated with thyroid diseases result from altered thyroid hormone action or whether they are a consequence of a direct effect of TSH on endothelial cells. The present study was designed to evaluate the endothelial response of coronary flow to TSH in patients with differentiated thyroid cancer (DTC) without cardiovascular risk factors.', 'The study population consisted of three men and seven women (M', 'Left ventricular morphology and systolic and diastolic function were normal in all patients. Levels of thyroid hormones and thyroglobulin and antithyroglobulin antibodies did not differ significantly pre- versus post-rhTSH treatment, whereas TSH levels were higher after rhTSH administration. Blood pressure and heart rate were not affected by rhTSH. Coronary flow peak velocity at rest (22.3\u2009±\u20096 vs 23.2\u2009±\u20098.7; p\u2009=\u20090.66) did not differ between baseline and 24\u2009h after rhTSH, while post-CPT velocity (29.3\u2009±\u20096.8 vs 34.4\u2009±\u200910.9; p\u2009<\u20090.05) and the CFR were higher after rhTSH administration (1.32\u2009±\u20090.2 vs. 1.53\u2009±\u20090.2; p\u2009<\u20090.01).'] Does recombinant Human Thyrotropin improve Endothelial Coronary Flow Reserve in Thyroidectomized Patients with Differentiated Thyroid Cancer?